{"disease":{"id":"progressive-familial-intrahepatic-cholestasis","name":"progressive familial intrahepatic cholestasis"},"drugs":{"marketed":[{"drug_id":"odevixibat","indication_name":"Pruritus in progressive familial intrahepatic cholestasis (PFIC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bylvay","generic_name":"ODEVIXIBAT","company_name":"Ipsen","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"Ileal Bile Acid Transporter Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Bylvay works by blocking the ileal sodium/bile acid cotransporter, a protein that helps reabsorb bile acids in the intestines."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT03930810","title":"NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1500,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT07497724","title":"Retrospective Observational Study of Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT05704517","title":"Progressive Familial Intrahepatic Cholestasis in Indian Children - Establishing an Indian PFIC Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT07191704","title":"A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03659916","title":"Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Albireo, an Ipsen Company","has_results":true},{"nct_id":"NCT03905330","title":"A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04185363","title":"An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06193928","title":"Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07317193","title":"DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","has_results":false},{"nct_id":"NCT07293897","title":"A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02057718","title":"Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04729751","title":"A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04071197","title":"Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"National Liver Institute, Egypt","has_results":false},{"nct_id":"NCT07185919","title":"A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea","phase":"","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03082937","title":"An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Albireo","has_results":false},{"nct_id":"NCT05543187","title":"A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03353454","title":"A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04483531","title":"Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Albireo","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}